Veracyte, Inc.
VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$42.31
Price+1.25%
$0.52
1Y
Price
Market Cap
$3.376b
Mid
Price/Earnings 3y Avg5y Avg
21.2x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+16.2%
EBITDA Margin+17.0%
Net Profit Margin+28.6%
Free Cash Flow Margin+16.2%
EBITDA Margin+17.0%
Net Profit Margin+28.6%
Free Cash Flow MarginRevenue
$561.900m
+8.7%
1y CAGR+16.0%
3y CAGR+17.5%
5y CAGREarnings
$114.483m
+72.5%
1y CAGR+126.6%
3y CAGR+69.1%
5y CAGREPS
$1.40
+70.7%
1y CAGR+121.9%
3y CAGR+66.4%
5y CAGRBook Value
$1.388b
$1.486b
Assets$97.963m
Liabilities$40.107m
DebtDebt to Assets
2.7%
0.3x
Debt to EBITDAFree Cash Flow
$165.455m
+30.7%
1y CAGR+71.8%
3y CAGR+923.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company